Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Efficacy of CAR-BCMA T Cells in Refractory or Relapsed Multiple Myeloma
NCT03716856Phase 1Unknown
- Sponsor
- First Affiliated Hospital, Zhejiang University School of Medicine
- Start
- Mar 2018
- Primary completion
- Jun 2020
- Modality
- Gene Editing, Gene Silencing, CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of zevorcabtagene autoleucel in multiple myeloma (MM), sponsored by First Affiliated Hospital, Zhejiang University School of Medicine. Primary endpoints: Incidence of study related adverse events at 24 weeks and Engraftment potential at 2 years. Status: unknown.
02
Drugs
zevorcabtagene autoleucel
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT03716856.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03716856.